Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study
Sponsor: Borstkanker Onderzoek Groep
A PHASE3 clinical study on Breast Cancer and HER2 Positive, this trial is ongoing. The trial is conducted by Borstkanker Onderzoek Groep and has accumulated 14 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Apr 2023 — Apr 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 9 earlier versions
-
Nov 2022 — Apr 2023 [monthly]
Active Not Recruiting PHASE3
-
Apr 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE3
-
Nov 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Feb 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Borstkanker Onderzoek Groep
- Roche Pharma AG
- The Netherlands Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
's-Hertogenbosch, Netherlands, Alkmaar, Netherlands, Almelo, Netherlands, Amsterdam, Netherlands, Beverwijk, Netherlands, Breda, Netherlands, Delft, Netherlands, Deventer, Netherlands, Ede, Netherlands, Eindhoven, Netherlands and 19 more location s